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The matrix metalloproteinases (MMPs) are a family of zinc ion
(Zn2+)-dependent enzymes, which, collectively, are able to degrade
all the protein components of the extracellular matrix (ECM)
(Matrisian, 1992; Kleiner and Stetler-Stevenson, 1993). The activity
of these enzymes is normally tightly regulated in order to control
their destructive potential (Cottam and Rees, 1993). In recent years,
however, evidence has accumulated that aberrant constitutive
expression and activation of MMPs may be important in tumour
progression and metastasis (Liotta and Stetler-Stevenson, 1990;
Stetler-Stevenson et al, 1996). The breakdown of the ECM
surrounding tumours by the action of MMPs would permit local
invasion, and the loss of local tissue architecture may promote angio-
genesis of the developing tumour. In addition, dissolution of the
basement membrane facilitates intravasation and extravasation of
tumour cells, essential steps in metastatic dissemination. The hypoth-
esis that MMPs are intimately involved in tumour progression has
been supported by studies with various small molecular weight
inhibitors of these enzymes, which have been shown to inhibit
tumour growth, metastasis and angiogenesis in a number of animal
models (Davies et al, 1993; Wang et al, 1994; Watson et al, 1995;
Anderson et al, 1996; Eccles et al, 1996; Giavazzi et al, 1998).
Several MMP inhibitors have now reached the stage of clinical eval-
uation. The current study was prompted by the use of cancer antigens
in the early trials of one of the first of these inhibitors, marimastat.
Since MMP inhibitors are not cytotoxic, it is predicted that
marimastat may cause a reduction in the rate of tumour growth
rather than inducing the tumour shrinkage which occurs with
conventional, cytotoxic chemotherapeutics. For this reason it was
considered likely that standard determinants of tumour response to
therapy, namely radiological and clinical measurements, may not
detect the clinical activity of marimastat.
An alternative approach, the measurement of changes in circu-
lating levels of serum cancer antigens, was, therefore, used to eval-
uate the activity of marimastat in early studies. Tumour antigen
levels have been used for many years in the clinical management
of cancer (Goldenberg et al, 1981). They have proved of value in
detecting recurrent disease (NIH Consensus Statement, 1981;
Hida et al, 1996), monitoring the effects of chemotherapy and
predicting prolonged survival (Hine and Dykes, 1984; Allen-
Mersh et al, 1987; Ward et al, 1993). A combined analysis of mari-
mastat clinical trials, in patients with carcinoma of the pancreas,
ovary, colon and prostate, has demonstrated a dose-dependent
reduction in the rate of rise of cancer antigens (Nemunaitis et al,
1998). These modifications in antigen levels are presumed to
reflect changes in the progression of the disease. However, the rate
of rise of tumour antigens is an unvalidated measure of disease
progression and there has been some controversy over the
approach taken in the trials of marimastat (Gore et al, 1996; Millar
et al, 1996). It is possible that a decrease in circulating antigen
levels may be a direct effect of the inhibitor on the processing of
cell surface associated antigens by MMPs or the suppression of
cancer antigen production, rather than, or in addition to, inhibition
of the progression of the disease.
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Summary Inhibition of matrix metalloproteinases (MMPs) is an attractive approach to adjuvant therapy in the treatment of cancer. Marimastat
is the first orally administered, synthetic MMP inhibitor to be evaluated, in this capacity, in the clinic. Measurement of the rate of change of
circulating tumour antigens was used for evaluating biological activity and defining optimum dosage in the early clinical trials of marimastat.
Although tumour antigen levels have been used in the clinical management of cancer for many years, they have not been validated as
markers of disease progression. In order to investigate the relationship between the effects of marimastat on tumour growth and circulating
tumour antigen levels, mice bearing the human gastric tumour, MGLVA1, were treated with marimastat. The MMP inhibitor exerted
a significant therapeutic effect, reducing tumour growth rate by 48% (P = 0.0005), and increasing median survival from 19 to 30 days
(P = 0.0001). In addition, carcinoembryonic antigen (CEA) levels were measured in serum samples from animals sacrificed at regular
intervals, and correlated with excised tumour weight. It was shown that the natural log of the CEA concentration was linearly related to the
natural log of the tumour weight and that treatment was not a significant factor in this relationship (P = 0.7). In conclusion, circulating CEA
levels were not directly affected by marimastat, but did reflect tumour size. These results support the use of cancer antigens as markers of
biological activity in early phase trials of non-cytotoxic anticancer agents.
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Correspondence to: EA BoneThe purpose of the current study was to investigate the relation-
ship between inhibition of tumour growth by marimastat and
changes in circulating carcinoembryonic antigen (CEA) levels.
MATERIALS AND METHODS
Cell culture
The effect of marimastat on CEA shedding in vitro was investigated
using the human colon adenocarcinoma cell line, LS174T. The cells
were seeded at 3 ´ 105 per well and incubated at 37°C in a humidi-
fied atmosphere of 5% carbon dioxide for 48 h, reaching 80—100%
confluence. The medium was removed and the cells washed once
with fresh medium. An aliquot of medium containing the appro-
priate concentration of marimastat was added to the cells, and the
incubation was continued for a further 28 h. The supernatants were
removed, placed in siliconized tubes, spun and decanted into fresh
tubes. Samples were frozen at — 20°C prior to assay.
Animal handling
Male and female 6 to 8-week-old MF1 nu/nu nude mice (Cancer
Studies Unit, University of Nottingham) were used in all experi-
ments. The animals were maintained in sterile isolation at 26°C
and received food and water ad libitum. All experimentation was
performed according to UKCCCR guidelines.
Tumour
The human gastric cell line MGLVA1 (Watson et al, 1991) is an
ascites variant of the gastric carcinoma line, MKN45G. The latter, a
gastrin-producing line, is a clonal variant of MKN45, established
in vivo in hypergastrinaemic nude mice (Watson et al, 1990). The
parental line, MKN45, was derived from a 62-year-old woman with
gastric cancer (Hojo, 1977). MGLVA1 was established by growing
MKN45G in the peritoneal cavity and passaging the ascitic cells
(Watson et al, 1991). This resulted in a more aggressive cell line
which reproducibly generated ascites as a monitorable condition
during tumour development, rather than just at the end-stage due to
high tumour burden. The parental line MKN45 has been used as a
CEA-secreting xenograft model (Pimm et al, 1992) and MKN45G
has been shown to retain CEA expression (Watson et al, 1991). In
the current study we have shown that the ascites variant, MGLVA1,
not only expresses CEA, but also that it is shed from the tumour
and can be detected in host serum.
MGLVA1 was maintained by serial passage in MF1 nude mice.
For experimental purposes, the tumour was removed from donor
animals at sacrifice, dissected from the capsule, minced finely into
3-mm3 pieces and pooled. Tumour pieces were implanted subcuta-
neously into the left flank of an equal number of male and female
nude mice under anaesthesia (Hypnorm/Hypnoval, Janssen).
Cross-sectional tumour measurements were taken twice weekly
from day 5 using callipers, and animals were weighed weekly
throughout the study.
In the initial study to examine the effects of marimastat on tumour
growth, mice were terminated once their tumour burden was greater
than 250-mm2, when their clinical condition became affected.
In the second study, which determined the effect of marimastat
on circulating CEA levels, four male and four female animals from
both the vehicle- and marimastat-treated groups were sacrificed
on days 4, 7, 11, 14, 17 and 21. In addition, marimastat-treated
animals were sacrificed on days 24, 27 and 30. At all early time
points mice were sacrificed randomly. At later time points (day 14
and thereafter) mice bearing tumours exceeding a cross-sectional
area of 250-mm2 were selected for termination. At termination,
mice were bled by cardiac puncture, the serum collected and
frozen at—20°C for subsequent CEA measurement. Tumours were
excised and weighed.
Treatment
Vehicle or marimastat (BB-2516; 2S,N1-dihydroxy-N4-{2,2-
dimethyl-1S-[(methylamino)carbonyl]propyl}-3R-isobutylbutan)
was administered at 0.5 ml h—1 by osmotic mini-pumps (Alzet
model 2002, Charles River, Kent, UK) implanted subcutaneously
on the right flank at the time of tumour grafting. Pumps were
replaced every 14th day. Marimastat was formulated at 15 mg ml—1
in 50% dimethyl sulphoxide—water. The dose delivered equates to
approximately 6.5 mg kg—1 day—1.
CEA measurement
CEA levels in the sera from mice and from cell culture super-
natants were measured using the automated IMx¤ Microparticle
Enzyme assay from Abbott Laboratories, according to the manu-
facturer￿s recommended protocol. In brief, the sample was incu-
bated with anti-CEA-coated microparticles, to which the antigen
binds. An aliquot of the incubation mixture was transferred and
bound irreversibly to a glass fibre matrix. Unbound material was
removed by washing and an anti-CEA—alkaline phosphatase
conjugate was applied to the filter. The conjugate bound to the
antibody—antigen complex, and excess conjugate was removed.
The substrate, 4-methyllumbelliferyl phosphate was added to the
matrix and the fluorescent product measured. Samples were
assayed neat, and at a 1 in 5 dilution.
Statistical analysis
In the first study one mouse was excluded from all analyses as the
tumour did not establish. Day 15 was the last day when all mice
were left alive. The two-sample t-test was used to test for differ-
ences between the treatment groups (marimastat or vehicle) in
cross-sectional area at day 15.
The time from tumour implant to sacrifice was presented using
Kaplan—Meier estimates and the treatment groups were compared
using the log-rank test. One mouse was censored as it was sacri-
ficed for reasons other than the cross-sectional area of the tumour.
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Figure 1 The effect of marimastat on shedding of cancer antigens from
cultured carcinoma cells in vitroAt sacrifice the tumours were excised and weighed. The rate of
tumour growth was calculated by dividing the tumour weight by
sacrifice time. The treatment groups were compared using the
Mann—Whitney U-test as the assumptions for the t-test were not
valid.
The relationship between the CEA levels, tumour weight and
treatment (marimastat or vehicle) was investigated using linear
regression. The natural log of the CEA levels was used due to the
skewness and heteroscedasticity of the data. The natural log of the
tumour weight was also used in order to satisfy the assumptions
for a linear regression analysis.
RESULTS
Effect of marimastat on shedding of CEA from cultured
cells
The effect of marimastat on the release of CEA into the culture
supernatant of cells was studied using the human colon adenocar-
cinoma cell line, LS 174T. This line is more amenable to culturing
in vitro than the MGLVA1 line which was used in the in vivo
models. Concentrations of marimastat, orders of magnitude higher
than those achieved in vivo, failed to inhibit the shedding of CEA
into the culture supernatant (Figure 1).
Measurement of circulating CEA
Previous studies have demonstrated that MGLVA1 and its parental
line express membrane-bound CEA (Watson et al, 1991). A
preliminary in vivo study showed that in blood from nude mice
bearing MGLAV1 tumours, CEA was readily detectable; in
control animals with mean tumour weight of 2.2 g (s.e.m. =
0.191), the mean concentration of circulating antigen was
548 ng ml—1 (s.e.m. = 70.5).
Effect of marimastat on tumour growth
Treatment of nude mice bearing MGLVA1 xenografts with mari-
mastat significantly inhibited growth of the tumour as measured
by cross-sectional area at day 15 (mean cross-sectional area
104.66 mm2 compared with 233.75 mm2 for the vehicle group;
P < 0.0001, t-test). From day 15 onwards animals were sacrificed
as their tumour size reached > 250 mm2. Figure 2 shows the mean
cross-sectional area over time for the vehicle and marimastat
groups. A Kaplan—Meier curve was derived of time from tumour
implantation to sacrifice (Figure 3). Marimastat exerted a signifi-
cant effect (P = 0.0001, log-rank test), increasing median time to
reach a tumour burden of 250 mm2 from 19 days to 30 days.
Marimastat significantly reduced tumour growth rate compared to
vehicle-treated animals (0.0572 ± 0.00635 g day—1 compared to
0.1098 ± 0.099 g day—1; P = 0.0005, Mann—Whitney U-test).
Treatment with marimastat had no effect on animal weight gain
over the course of the study compared to vehicle-treated, tumour-
bearing controls (data not shown).
The ability of marimastat to inhibit the increase in cross-
sectional area of the tumour was confirmed in the second study
(Figure 4), which was primarily designed to measure CEA levels
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Figure 2 The effect of marimastat on the increase in cross-sectional area of
the human gastric carcinoma, MGLVA1, grown subcutaneously in nude mice
Figure 3 The time to reach the experimental endpoint in mice bearing the
MGLVA1 gastric xenograft
Figure 4 Confirmation of the inhibitory effect of marimastat on the growth of
the gastric carcinoma xenograft
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)throughout the course of tumour growth. No statistical analysis
was performed on the cross-sectional area measurements from this
study as a bias was introduced from day 14, after which animals
with large tumours were selected to be sacrificed: this tended to
reduce the mean tumour weight in the vehicle-treated group to a
greater extent than the marimastat-treated group.
CEA analysis
CEA levels were measured in serum samples from animals sacri-
ficed at regular intervals throughout the course of the second
study, and correlated with the excised tumour weight of the appro-
priate animal. The tumour weights ranged from 0.05 to 2.17 g and
from 0.06 to 1.55 g in the vehicle- and marimastat-treated
groups respectively. The CEA concentrations ranged from 6 to
809 ng ml—1, and from 4 to 679 ng ml—1 in the two groups
respectively.
The relationship between the CEA levels, tumour weight and
treatment was evaluated by linear regression. In order to satisfy the
assumptions for such analysis, the natural logs of both CEA
concentration and tumour weight were used. The logn of CEA
concentration was found to be linearly related to the logn of the
tumour weight by the following formula:
logn (CEA) = 5.58 + 1.34 ´ logn (weight).
It was found that treatment was not a significant term in the model
(P = 0.7, F-test) and, therefore, was not related to the logn CEA
levels. The data depicted in Figure 5 show that treatment with
marimastat does not influence the distribution of the data set.
DISCUSSION
Gastric malignancy has previously been shown to be associated
with overexpression of MMPs (D￿Errico et al, 1991; McDonnell et
al, 1991; Honda et al, 1996). The studies described in this report
show that marimastat has a marked and significant inhibitory
effect upon the growth of the gastric carcinoma xenograft,
MGLVA1, subcutaneously implanted in nude mice; measurement
of the cross-sectional area of the tumour, rate of increase of tumour
weight and time of sacrifice all show the benefit of treatment with
marimastat.
In these studies marimastat was delivered by osmotic mini-
pump. In contrast to the pharmacokinetic profile observed in
humans (Nemunaitis et al, 1998), the blood concentration of
marimastat attained in rodents following oral administration is
markedly lower and of shorter duration (unpublished observa-
tions). Therefore, in order to demonstrate significant efficacy in
rodent cancer models it has been necessary to deliver marimastat
continuously by subcutaneously implanted mini-pumps. The
differences in metabolism of marimastat between the species also
accounts for the apparently higher dose delivered to the mice
(6.5 mg kg—1 day—1) compared to those being used in phase III clin-
ical trials (5—25 mg b.i.d.). The steady-state blood concentration of
marimastat in the mice is similar to the mean trough levels
achieved in patients.
This study is the first published demonstration of anti-cancer
activity for marimastat, and confirms the belief, substantiated by
many studies with the related MMP inhibitor batimastat (Davies et
al, 1993; Chirivi et al, 1994; Sledge et al, 1995; Taraboletti et al,
1995; Watson et al, 1995), a non-orally bioavailable drug, that
MMPIs have promise as anti-cancer therapies.
Levels of circulating CEA have previously been used as a surro-
gate marker of the therapeutic effect of marimastat in patients with
various carcinomas (Millar and Brown, 1996; Nemunaitis et al,
1998; Primrose et al, 1999). Studies were, therefore, instigated to
confirm the validity of such an approach. Initial experiments
investigating the effect of marimastat on the release of CEA from
cells cultured in vitro showed that, even at a very high concentra-
tion, the MMPI was unable to inhibit the appearance of CEA in the
culture supernatant. These data, whilst interesting, may not neces-
sarily reflect the mechanism of antigen shedding in vivo, as the
culture system does not account for the potential involvement of
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Figure 5 Relationship between treatment, log of tumour weight and log of circulating carcinoembryonic antigen levelshost factors mediating the release of the antigen from the cell
surface. In vivo studies were, therefore, designed to investigate the
effect of tumour size and treatment regime on the concentration of
circulating CEA.
Animals bearing MGLVA1 tumours were sacrificed at regular
intervals throughout the course of the development of the tumours.
Groups of animals treated with marimastat were sacrificed at later
time points than untreated animals in order to account for the
inhibitory effect of marimastat on tumour growth, thereby
ensuring that the distribution of tumour size in the treated and
untreated groups were similar. As is clear from the graphical
depiction (Figure 5), the correlation between tumour weight and
circulating CEA levels was independent of whether the samples
derived from an animal that had been treated with marimastat or
vehicle. These observations were confirmed by statistical methods,
which demonstrated that the natural log of CEA concentration was
linearly related to the natural log of the tumour weight, and that
treatment was not a significant term in the statistical model. This
indicates that marimastat has no direct effect on the metabolism of
CEA in vivo, and that antigen levels are directly related to tumour
size alone. It is reasonable to conclude, therefore, that circulating
tumour antigen levels are a valid indicator of the progression of the
disease, at least over the period the tumour is growing exponen-
tially, and justifies their use as surrogate markers of biological
activity in early phase clinical trials of non-cytotoxic anti-cancer
agents.
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